Thailand Newswire

Hitachi booth concept for CES 2026TOKYO, Dec 4, 2025 - (JCN Newswire via SeaPRwire.com) - Hitachi, Ltd. (TSE:6501, “Hitachi”) today announced its exhibition plans for CES 2026, to be held January 6 to 9, where it will unveil innovative solutions and technology roadmaps for a harmonized society.For over a century, Hitachi has been at the forefront of social innovation, combining Information Technology (IT), Operational Technology (OT), and physical products to transform businesses, governments, and communities. This long-standing legacy is now accelerated by the application of cutting-edge AI.Hitachi’s commitment to social innovation is guided by a simple yet profound question: “What’s next?” This question shapes its CES 2026 experience, which will be hosted at Booth 8529 in the Las Vegas Convention Center’s North Hall.For more details, the Hitachi CES 2026 event site will launch soon at https://hitachidigital.com/hitachi-at-ces-2026/.Innovations Inspired by Today’s ChallengesHitachi’s CES demonstrations address the most compelling societal needs in areas such as energy, mobility, digital technologies, and industrial automation. These technical showcases highlight how Hitachi enables clients to transform by creating new solutions and business models that leverage the power of AI.Hitachi Presentation at CES FoundryHitachi will introduce a groundbreaking AI initiative during CES Foundry, a two-day event focused on AI advancements. A presentation with NVIDIA will explore innovations in physical AI and its transformative potential in real-world applications.Session: Pioneering Industrial AI TechnologiesSpeakers: Arya Barirani, Chief Marketing Officer, Hitachi Digital/Deepu Talla, VP & GM, Robotics & Edge AI, NVIDIADate/Time: Thursday, January 8 @ 11:00 a.m.Location: The Fontainebleau Las Vegas (Discovery Stage)Explore Hitachi’s Deep Capabilities at CESHitachi’s booth will show its solutions through six themed zones, each offering a glimpse into the future of mobility, energy, innovation, and industry. The demonstrations will also include HMAX—Hitachi’s signature solution embodying physical AI technologies.Hitachi AI-Powered Solution Suite “HMAX”This zone showcases how AI is transforming industries via HMAX, Hitachi’s AI-powered solutions for AI in the physical world. From reimagining power grids to enhancing manufacturing and mobility, visitors will see how Hitachi’s expertise in industrial technology, data, and AI drives a more efficient, autonomous future.EnergyDiscover Hitachi’s innovative energy solutions designed to ensure a stable, eco-friendly power supply. From monitoring infrastructure to optimizing resources and preventing outages, Hitachi’s technologies support sustainable energy for homes, businesses, and data centers.MobilityExplore how HMAX technology is revolutionizing transportation with modern electrified solutions. By combining AI with advanced domain technologies, Hitachi is automating transportation infrastructure management and improving passenger experiences while reducing energy consumption, emissions, and maintenance disruptions.Data, AI, and DigitalThis zone highlights applications ranging from intelligent software-defined vehicles to cloud-based AI solutions, demonstrating how digital advancements underpinned by deep digital engineering capabilities are driving progress for clients and society.Integrated Industry AutomationLearn how Hitachi enables the factories of the future with cutting-edge industrial automation solutions. From smart buildings to intelligent products, this zone showcases technologies that are transforming manufacturing and beyond.Research & Development for New HorizonsStep into the future with Hitachi’s R&D demos, showing bold solutions in areas like AI-enhanced frontline worker efficiencies, autonomous manufacturing innovations, and more. This zone offers a glimpse into the technologies that will shape the next two decades and enrich everyday life.In-Booth PresentationsHitachi will host a series of 10-minute technical presentations at its Innovation Theater. These sessions will feature insights from Hitachi’s group companies and partners, offering a front-row seat to groundbreaking ideas and transformative solutions.Meet With UsHitachi representatives from each technology area will be available for on-site briefings. To schedule a meeting, please contact Hitachi’s Briefing Center (sylvia.barranti@hitachidigital.com).About Hitachi, Ltd.Through its Social Innovation Business (SIB) that brings together IT, OT (Operational Technology) and products, Hitachi contributes to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates globally in four sectors – Digital Systems & Services, Energy, Mobility, and Connective Industries – and the Strategic SIB Business Unit for new growth businesses. With Lumada at its core, Hitachi generates value from integrating data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2024 (ended March 31, 2025) totaled 9,783.3 billion yen, with 618 consolidated subsidiaries and approximately 280,000 employees worldwide. Visit us at www.hitachi.com. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Kawasaki, Japan and Paris, France, Dec 4, 2025 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited and Scaleway, the leading European public cloud provider for AI builders, today announced a strategic collaboration towards the establishment of a sustainable AI utilization environment that also ensures data sovereignty. By combining Fujitsu’s advanced processor development expertise with Scaleway's European cloud infrastructure expertise, the two companies aim to evaluate new ways to support efficient, responsible and secure AI deployment at scale. The collaboration, which commenced on November 27th with the signing of an MoU, will see Fujitsu combine its high-performance, energy-efficient Arm-based FUJITSU-MONAKA CPU platform and development capabilities with Scaleway's cloud infrastructure expertise.As part of their collaboration, Fujitsu and Scaleway will explore a new CPU-based option for AI inference processing for AI builders and enterprises in the European market, complementing traditional GPU-centric configurations. The companies will conduct joint testing and validations to create optimal infrastructure environments tailored to specific workloads. This will enable customers to select the most suitable platform based on their AI workload characteristics and Total Cost of Ownership (TCO) and help to address societal challenges such as increasing AI power consumption and supply chain risks.Through this collaboration, Fujitsu and Scaleway will contribute to the healthy development of a digital society in Europe by offering an energy-efficient CPU-based alternative alongside powerful GPU platforms, thereby supporting customers' business growth and Green Transformation (GX).Naoki Shinjo,SVP, Head of Advanced Technology Development Unit, at Fujitsu Limited, comments:“As AI's evolution accelerates at an incredible pace, its energy consumption has become a critical global challenge. The demand for optimal, flexible infrastructure to handle diverse workloads remains an urgent task. Our partnership with Scaleway is set to revolutionize this landscape. By fusing our cutting-edge technologies and deep expertise, we will create a truly power-efficient, CPU-based computing platform. This isn't just about optimizing our customers' Total Cost of Ownership and fueling their business growth; it's a powerful stride towards accelerating Europe's green transformation and building a sustainable future for everyone."Yann-Guirec Manac'h, Head of Hardware R&D at Scaleway, comments:“At Scaleway, our commitment to delivering unparalleled power efficiency in the cloud remains at the heart of everything we do, driving us to continuously innovate for a sustainable digital future.We are proud to announce our collaboration with Fujitsu, a partnership that will allow us to unlock new possibilities in efficient, responsible, and continuous AI innovation. By integrating FUJITSU-MONAKA CPU into our infrastructure, we aim to enhance our offerings and empower our customers with cutting-edge AI solutions. This collaboration not only strengthens our ability to meet the evolving demands of the market but also ensures that our customers have access to the most advanced, sustainable, and high-performance AI technologies tailored to their unique needs.”Accelerating sustainable transformation and data sovereignty in EuropeThe rapid proliferation of generative AI has dramatically increased data center power consumption, creating a global societal challenge. In Europe, this has led to increased demand for infrastructures that reconcile performance, energy efficiency and data sovereignty. Specifically, many organizations now operate AI models continuously in production and require predictable performance, controlled operating costs and a reduced environmental footprint. CPU-based architectures are particularly well suited to these requirements because they offer stable performance, efficient energy use and simple integration within existing environments.Fujitsu, with its advanced computing technologies, is developing the FUJITSU-MONAKA processor, which employs world-leading technologies cultivated in its supercomputer development activities. Built on leading-edge 2-nanometer technology and featuring unique technologies such as its own microarchitecture optimized for advanced 3D packaging and ultra-low voltage circuit operation, it is designed to deliver both high performance and power efficiency across diverse computing applications including enterprise AI.Aligning with its objective to provide organizations, from innovative startups to large enterprises, with infrastructure that matches their operational and strategic requirements, Scaleway offers a full spectrum of cloud services, from its AI Factory with powerful GPUs to highly efficient computing infrastructure, to offer the appropriate architecture for each use case while maintaining full transparency on performance, cost and environmental impact.Building on their ongoing discussions to define key use cases, the two companies will commence this joint Proof of Concept (PoC) in the second half of 2026. Based on the results, the parties will consider establishing and providing pilot environments for customers from 2027 onwards. Moving forward, Fujitsu and Scaleway will explore the commercialization of new CPU-based AI inference services optimized for the European market.[1] FUJITSU-MONAKA:This new technology applied to FUJITSU-MONAKA is based on results obtained from a project subsidized by the New Energy and Industrial Technology Development Organization (NEDO).About FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuAbout Scaleway SASScaleway is the European leader in public cloud and a true alternative to the US hyperscalers. A subsidiary of the iliad Group, Scaleway combines decades of infrastructure expertise with the agility of a state-of-the-art tech company. With a rapidly expanding network of data centers, Scaleway offers a comprehensive portfolio of high-performance cloud services, from virtual machines to advanced data management solutions, cloud-native infrastructure and AI-optimized supercomputers. Championing open standards and operating within a fully European framework, Scaleway provides a secure and transparent cloud environment that meets the needs of organizations with the highest digital sovereignty requirements. Find out more: www.scaleway.comPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiriesScaleway SASpresse@scaleway.com  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan — Dec 4, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Orchestrating Future Fund (*1), an ecosystem-based corporate venture capital (CVC) fund, has invested in PopID, Inc. (PopID), a U.S.-based provider of face authentication payment services. The investment strengthens NEC’s position in next-generation digital transactions by combining its world-leading biometric authentication technology with PopID’s rapidly growing payment platform.Together, NEC and PopID aim to establish a new global standard for secure, seamless, and privacy-centric digital transactions, delivering convenience for consumers and efficiency for businesses.Strategic Value of the InvestmentThe new funding builds on PopID’s recent Series C round in May 2025, led by Verifone, a leader in North American in-store payment terminals, along with Visa, Cultivate Next (Chipotle’s venture arm), Commerce Ventures, PayPal, and additional leading companies. The funding enables the full-scale rollout of Verifone terminals compatible with PopID across North America.By investing at this pivotal stage, NEC will accelerate the adoption of biometric payments, extending the global reach of its secure authentication technologies. This partnership supports NEC’s vision of creating flexible, resilient, and sustainable digital societies.PopID’s Growing Presence and Customer ValuePopID has quickly scaled its platform to more than 1,000 merchants across the United States, including major quick-service chains such as Whataburger and Steak ‘n Shake. Through the PopID app, users register their face and can complete payments at participating stores-without the need for cards, cash or phones. This provides a faster and touch-free checkout experience, while NEC’s biometric technology ensures strong data protection by converting face data into non-reversible templates.For consumers, the result is a secure, convenient, and hygienic way to pay. For merchants, PopID increases throughput and revenue while also reducing transaction fees by supporting debit, credit, and ACH payment rails.NEC’s Biometric LeadershipNEC’s face authentication technology has consistently ranked No. 1 in accuracy in benchmark tests conducted by the U.S. National Institute of Standards and Technology (NIST) (*2). With operations spanning more than 50 countries, NEC is advancing the social implementation of face authentication across payments, retail, and enterprise services."The NEC Orchestrating Future Fund invests in startups that are pioneering new markets with cutting-edge technologies and innovative business models," said Shigeki Wada, Corporate SVP, NEC Corporation. "PopID's advanced payment service contributes to the global adoption of face authentication payments and aligns with NEC's vision of creating flexible, resilient, and sustainable societies. Together with PopID, we will accelerate our efforts to create new social value."PopID Comment"We are excited to work with NEC, a global leader in biometric authentication technology, to bring the full biometric experience—from entry to payments—to stadiums and theme parks around the world," said John Miller, CEO of PopID and Chairman of the Cali Group.*1) NEC Orchestrating Future FundAn ecosystem-type corporate venture capital fund in which multiple companies that share NEC's vision of the future of society, "NEC 2030VISION," participate.*2) Ranked No. 1 multiple times in the face authentication benchmark test by the U.S. National Institute of Standards and Technology (NIST).https://www.nec.com/en/global/solutions/biometrics/face/index.html*The results by NIST do not imply endorsement of any system, product, service, or company by the U.S. government.About PopIDPopID is a Los Angeles-based provider of consumer-initiated biometric identity and payment technology. Its platform enables face or palm verification so people can check in access loyalty, place orders, and complete transactions at participating locations. PopID uses opt-in enrollment, and it integrates with common point-of-sale and payment systems to fit existing workflows. The company’s goal is to provide a universal gateway for identity across everyday interactions-from entry to checkout. To learn more about PopID and its offerings, visit www.popid.com.About NECNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and CAMBRIDGE, Mass., Dec 4, 2025 - (JCN Newswire via SeaPRwire.com) -  Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings on time savings with continued treatment with humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody lecanemab (generic name, U.S. brand name LEQEMBI®)  were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference. Additionally, a scientific symposium was held on the subcutaneous formulation (SC-AI), which was approved for maintenance treatment in the United States in August 2025, and the rolling supplemental Biologics License Application (sBLA) for initiation treatment was completed in November 2025. The application for a subcutaneous injectable formulation in Japan was submitted in November 2025.Alzheimer's disease (AD) is a progressive, relentless disease with Aβ and tau as hallmarks, that is caused by a continuous underlying neurotoxic process driven by protofibrils* (PF) that begins before amyloid plaque removal and continues afterward.1,2,3 Only LEQEMBI fights AD in two ways - targeting both PF and amyloid plaque, which can impact tau downstream. Estimating the 10-Year Time-Savings Benefits of Lecanemab Treatment (Presentation: December 3, 2:40 PM PT)This analysis used data from the Clarity AD open-label extension (OLE) and 16 clinical studies of monoclonal antibodies for AD to estimate long-term AD progression over 10 years and the slowing effect of continued lecanemab treatment. The analysis evaluated estimated "time savings" (slowing of disease progression) compared to natural decline based on ADNI** (Alzheimer's Disease Neuroimaging Initiative) data (untreated group), using Clinical Dementia Rating - Sum of Boxes (CDR-SB). These results suggest that early initiation and long-term lecanemab treatment may continue to slow AD progression and help maintain cognitive function over a longer period.Findings from each group:Time Savings from Mild Cognitive Impairment (MCI) Due to AD to Mild ADThe time to progression from MCI due to AD to mild AD was 7.2 years in the untreated group, whereas with continued LEQEMBI treatment to the onset of moderate AD, progression to mild AD took 9.7 years, indicating a time savings of 2.5 years.In the low-amyloid group (patients who started treatment at an early stage: amyloid PET <60 centiloids), the time to progression from MCI to mild AD was 13.2 years with continued LEQEMBI treatment to the onset of moderate AD, suggesting a time savings of 6.0 years.Time Savings from MCI due to AD to Moderate ADThe time to progression from MCI  due to AD to moderate AD was 10.1 years in the untreated group, whereas with continued LEQEMBI treatment to the onset of moderate AD, progression to moderate AD took 13.6 years, indicating a time savings of 3.5 years.In the low-amyloid group, the time to progression with continued LEQEMBI treatment to the onset of moderate AD, progression to moderate AD took 18.4 years, suggesting a time savings of 8.3 years.These findings indicate that earlier initiation of lecanemab treatment may provide a greater delay in disease progression. Furthermore, each additional year on LEQEMBI could further delay disease progression compared to stopping treatment, even long after plaque is expected to have been cleared.Lecanemab Subcutaneous Formulation for Treatment Initiation in Early Alzheimer’s Disease: Optimizing Patient Care with a Potential New Option (Symposium Presentation: December 3, 3:10 PM)In this symposium, the latest data from the lecanemab subcutaneous clinical development program were presented focusing on treatment initiation, including results from the subcutaneous (SC) formulation subcohort (n=273) in the Clarity AD trial open-label extension (OLE).. It was shown that weekly administration of lecanemab SC-AI at 500 mg (two 250 mg injections) demonstrated bioequivalence in drug exposure compared to intravenous dosing of 10 mg/kg every two weeks (exposure ratio: 104%, 90% CI: 99.1%–109%).Based on clinical data and modeling analysis, the effect on amyloid removal in the brain and safety (ARIA-E incidence) was shown to be independent of the route of administration and explained by exposure, suggesting that weekly 500 mg SC dosing provides similar efficacy and safety to biweekly 10 mg/kg IV dosing. Additionally, ARIA-E incidence was also predicted to be comparable between SC and IV administration (12.4% overall, 30.9% in ApoE4 homozygotes).In this sub-cohort which had prior exposure to lecanemab, safety evaluation showed systemic infusion reactions occurred in 0% of patients receiving 500 mg SC, all of whom had previously received IV lecanemab, and 1.4% of patients who initiated on 720 mg SC by vial, which is favorable compared to systemic infusion reactions in the IV group (26.4%). Immunogenicity assessment indicated a low incidence of anti-drug antibodies (ADA) at 1.4%.These results indicate that the subcutaneous formulations of lecanemab, designed with consideration for the convenience of patients and their care partners, maintains efficacy with a low incidence of systemic infusion reactions, and is otherwise equivalent to conventional IV administration.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are thought to be the most toxic Aβ species that contribute to brain damage in AD and play a major role in the cognitive decline of this progressive and devastating disease. Protofibrils can cause neuronal and synaptic damage in the brain, which can subsequently adversely affect cognitive function through multiple mechanisms.3 The mechanism by which this occurs has been reported not only by increasing the formation of insoluble Aβ plaques, but also by directly damaging signaling between neurons and other cells. It is believed that reducing protofibrils may reduce neuronal damage and cognitive impairment, potentially preventing the progression of AD. 4** ADNI is a clinical research project launched in 2005 to develop methods to predict the onset and progression of AD and to confirm the effectiveness of treatments. The project involves a multi-year longitudinal observation targeting healthy elderly individuals as well as patients with mild cognitive impairment (MCI) and early stages of AD.MEDIA CONTACTSEisaiEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Eisai Europe, Ltd.EMEA Communications Department+44 (0) 7974-879-419Emea-comms@eisai.netEisai Inc. (U.S.)Libby Holman+1-201-753-1945Libby_Holman@eisai.comBiogen Inc.Madeleine Shin+ 1-781-464-3260public.affairs@biogen.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0)3-3817-5122Biogen Inc.Tim Power+ 1-781-464-2442IR@biogen.comFor more details, please visit: https://www.eisai.com/news/2025/news202585.html  Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com